Online inquiry

IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ137MR)

This product GTTS-WQ137MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Kidney tumours research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ137MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ629MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ4048MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ1530MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ11793MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ6376MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ1602MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ7844MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ2385MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW